Depakine, known in Chinese as 帝拔癲, contains Sodium valproate + Valproic acid.

Indications: Grand mal epilepsy, petit mal epilepsy, mixed types, and temporal lobe epilepsy; manic episodes.
Precautions:

1. Patients with acute or chronic hepatitis.
   
2. Patients with a family history of severe hepatitis, especially drug-induced hepatitis.
   
3. Valproic acid may cause fatal hepatotoxicity; monitor blood drug concentration within the first six months of treatment.
   
4. Valproic acid has been reported to cause fatal pancreatitis. If patients show symptoms of pancreatitis, such as abdominal pain, nausea, vomiting, etc., seek medical attention immediately. Discontinue medication immediately if pancreatitis is confirmed.
   
5. Valproic acid may cause thrombocytopenia and inhibit platelet aggregation. Monitor platelet count, bleeding time, and coagulation tests before and during treatment or before surgery.
   
6. Reduce dosage in patients with renal insufficiency.
   
7. Enteric-coated tablets are hygroscopic and should not be split or crushed.
   
8. Concomitant use with mefloquine is prohibited.
   

Depakine oral administration has a bioavailability close to 100%, with a half-life of about 15-17 hours. Blood concentration reaches a steady state within three to four days and is primarily excreted through urine.

Side effects: Gastrointestinal discomfort, nausea, dyspepsia, drowsiness, weight gain, hair loss, hand tremors.

Pregnancy category D

Source: http:/ / www. liverx. net/ 2007/ 0……% E5% B8% 9D% E6% 8B% 94% E7% 99% B2/